|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh P, Yam M, Russell PJ and Khatri A:
Molecular and traditional chemotherapy: A united front against
prostate cancer. Cancer Lett. 293:1–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seruga B, Ocana A and Tannock IF: Drug
resistance in meta-static castration-resistant prostate cancer. Nat
Rev Clin Oncol. 8:12–23. 2011. View Article : Google Scholar
|
|
5
|
Tao W, South VJ, Zhang Y, Davide JP,
Farrell L, Kohl NE, Sepp-Lorenzino L and Lobell RB: Induction of
apoptosis by an inhibitor of the mitotic kinesin KSP requires both
activation of the spindle assembly checkpoint and mitotic slippage.
Cancer Cell. 8:49–59. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Swanton C, Marani M, Pardo O, Warne PH,
Kelly G, Sahai E, Elustondo F, Chang J, Temple J, Ahmed AA, et al:
Regulators of mitotic arrest and ceramide metabolism are
determinants of sensitivity to paclitaxel and other
chemotherapeutic drugs. Cancer Cell. 11:498–512. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gascoigne KE and Taylor SS: Cancer cells
display profound intra- and interline variation following prolonged
exposure to antimitotic drugs. Cancer Cell. 14:111–122. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bekier ME, Fischbach R, Lee J and Taylor
WR: Length of mitotic arrest induced by microtubule-stabilizing
drugs determines cell death after mitotic exit. Mol Cancer Ther.
8:1646–1654. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hartwell LH, Mortimer RK, Culotti J and
Culotti M: Genetic control of the cell division cycle in yeast: V.
Genetic analysis of cdc mutants. Genetics. 74:267–286.
1973.PubMed/NCBI
|
|
10
|
Primorac I and Musacchio A: Panta rhei:
The APC/C at steady state. J Cell Biol. 201:177–189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pines J: Cubism and the cell cycle: The
many faces of the APC/C. Nat Rev Mol Cell Biol. 12:427–438. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gayyed MF, El-Maqsoud NM, Tawfiek ER, El
Gelany SA and Rahman MF: A comprehensive analysis of CDC20
overexpression in common malignant tumors from multiple organs: Its
correlation with tumor grade and stage. Tumour Biol. 37:749–762.
2016. View Article : Google Scholar
|
|
13
|
Schlabach MR, Luo J, Solimini NL, Hu G, Xu
Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, et al: Cancer
proliferation gene discovery through functional genomics. Science.
319:620–624. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang HC, Shi J, Orth JD and Mitchison TJ:
Evidence that mitotic exit is a better cancer therapeutic target
than spindle assembly. Cancer Cell. 16:347–358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mao Y, Li K, Lu L, Si-Tu J, Lu M and Gao
X: Overexpression of Cdc20 in clinically localized prostate cancer:
Relation to high Gleason score and biochemical recurrence after
laparoscopic radical prostatectomy. Cancer Biomark. 16:351–358.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Gao JZ, Du JL, Huang ZX and Wei LX:
Increased CDC20 expression is associated with development and
progression of hepatocellular carcinoma. Int J Oncol. 45:1547–1555.
2014.PubMed/NCBI
|
|
17
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al; TAX 327 Investigators. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mackinnon AC, Yan BC, Joseph LJ and
Al-Ahmadie HA: Molecular biology underlying the clinical
heterogeneity of prostate cancer: An update. Arch Pathol Lab Med.
133:1033–1040. 2009.PubMed/NCBI
|
|
19
|
Yu H: Cdc20: A WD40 activator for a cell
cycle degradation machine. Mol Cell. 27:3–16. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang L, Zhang J, Wan L, Zhou X, Wang Z and
Wei W: Targeting Cdc20 as a novel cancer therapeutic strategy.
Pharmacol Ther. 151:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Wan L, Zhong J, Inuzuka H, Liu P,
Sarkar FH and Wei W: Cdc20: A potential novel therapeutic target
for cancer treatment. Curr Pharm Des. 19:3210–3214. 2013.
View Article : Google Scholar
|
|
22
|
Manchado E, Guillamot M, de Cárcer G,
Eguren M, Trickey M, García-Higuera I, Moreno S, Yamano H, Cañamero
M and Malumbres M: Targeting mitotic exit leads to tumor regression
in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55α,δ
phosphatase. Cancer Cell. 18:641–654. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu
T, Liu J, Shaik S, Chen G, Deng J, et al: APC(Cdc20) suppresses
apoptosis through targeting Bim for ubiquitination and destruction.
Dev Cell. 29:377–391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff
KL, Oh DC, Hathaway N, Dimova N, Cuny GD and King RW: Pharmacologic
inhibition of the anaphase-promoting complex induces a spindle
checkpoint-dependent mitotic arrest in the absence of spindle
damage. Cancer Cell. 18:382–395. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeng X and King RW: An APC/C inhibitor
stabilizes cyclin B1 by prematurely terminating ubiquitination. Nat
Chem Biol. 8:383–392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sackton KL, Dimova N, Zeng X, Tian W,
Zhang M, Sackton TB, Meaders J, Pfaff KL, Sigoillot F, Yu H, et al:
Synergistic blockade of mitotic exit by two chemical inhibitors of
the APC/C. Nature. 514:646–649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Das T, Roy KS, Chakrabarti T, Mukhopadhyay
S and Roychoudhury S: Withaferin A modulates the Spindle assembly
checkpoint by degradation of Mad2-Cdc20 complex in colorectal
cancer cell lines. Biochem Pharmacol. 91:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang J, Thyagarajan-Sahu A, Krchňák V,
Jedinak A, Sandusky GE and Sliva D: NAHA, a novel hydroxamic
acid-derivative, inhibits growth and angiogenesis of breast cancer
in vitro and in vivo. PLoS One. 7:e342832012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang J, Jedinak A and Sliva D:
Ganodermanontriol (GDNT) exerts its effect on growth and
invasiveness of breast cancer cells through the down-regulation of
CDC20 and uPA. Biochem Biophys Res Commun. 415:325–329. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nasr T, Bondock S and Youns M: Anticancer
activity of new coumarin substituted hydrazide-hydrazone
derivatives. Eur J Med Chem. 76:539–548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maugeri-Saccà M, Vigneri P and De Maria R:
Cancer stem cells and chemosensitivity. Clin Cancer Res.
17:4942–4947. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Flahaut M, Meier R, Coulon A, Nardou KA,
Niggli FK, Martinet D, Beckmann JS, Joseph JM, Mühlethaler-Mottet A
and Gross N: The Wnt receptor FZD1 mediates chemoresistance in
neuroblastoma through activation of the Wnt/beta-catenin pathway.
Oncogene. 28:2245–2256. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hadjihannas MV, Bernkopf DB, Brückner M
and Behrens J: Cell cycle control of Wnt/β-catenin signalling by
conductin/axin2 through CDC20. EMBO Rep. 13:347–354. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bisson I and Prowse DM: WNT signaling
regulates self-renewal and differentiation of prostate cancer cells
with stem cell characteristics. Cell Res. 19:683–697. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ni J, Cozzi P, Hao J, Duan W, Graham P,
Kearsley J and Li Y: Cancer stem cells in prostate cancer
chemoresistance. Curr Cancer Drug Targets. 14:225–240. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song LN, Herrell R, Byers S, Shah S,
Wilson EM and Gelmann EP: Beta-catenin binds to the activation
function 2 region of the androgen receptor and modulates the
effects of the N-terminal domain and TIF2 on ligand-dependent
transcription. Mol Cell Biol. 23:1674–1687. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang F, Li X, Sharma M, Sasaki CY, Longo
DL, Lim B and Sun Z: Linking beta-catenin to androgen-signaling
pathway. J Biol Chem. 277:11336–11344. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yamada T, Takaoka AS, Naishiro Y, Hayashi
R, Maruyama K, Maesawa C, Ochiai A and Hirohashi S: Transactivation
of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin
complex in early colorectal carcinogenesis. Cancer Res.
60:4761–4766. 2000.PubMed/NCBI
|
|
39
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kimura Y, Morita SY, Matsuo M and Ueda K:
Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci.
98:1303–1310. 2007. View Article : Google Scholar : PubMed/NCBI
|
